An observational study in Cryptorchidism, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to male participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2025-10-03.
Sponsored by University Hospital, Montpellier · Observational
Cryptorchidism is the most frequent congenital defect of the male newborn. It requires surgery in childhood, increases the risk of fertility disorders and cancer. As a major public health objective, it's the subject of numerous recommendations. Its frequency is increasing in some countries faster than a single genetic cause could not explain it. It may occurs in a geographic cluster. The cause of cryptorchidism involves genetic, hormonal and environmental factors. Animal studies suggest that endocrine disruptors interfere with fetal testicular migration. The aim of the study is to find out if some environmental exposition may be associated with cryptorchidism.
Cryptorchidism is the most frequent congenital defect of the male newborn. It requires surgery in childhood, increases the risk of fertility disorders and cancer. As a major public health objective, it's the subject of numerous recommendations. Its frequency is increasing in some countries faster than a single genetic cause could not explain it. It may occurs in a geographic cluster. The cause of cryptorchidism involves genetic, hormonal and environmental factors. Animal studies suggest that endocrine disruptors interfere with fetal testicular migration. The aim of the study is to find out if some environmental exposition may be associated with cryptorchidism.
40 studies on the registry are indexed under Cryptorchidism; 14 are open to participants now.
This study's planned enrollment of 1,452 is above the median of 100 across 14 observational studies indexed under Cryptorchidism.
Browse Cryptorchidism studies →University Hospital, Montpellier is the lead sponsor of 1,261 studies on the registry; 224 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Parent of patient with cryptorchidism
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Parents of male children from the neonatal period to 18 years of age (during surgery) with cryptorchidism
Exclusion criteria:
parent exposition of endocrine disruptors
Other: Measure of the exposure of parent of male with /without cryptorchidism to endocrine disruptors
Parent exposition of endocrine disruptors
Other: Measure of the exposure of parent of male with /without cryptorchidism to endocrine disruptors
Measure of the exposure of parent of patient with/without cryptorchidism to endocrine disruptors (job exposure, during pregnancy)
frequency of the job exposure of the parents of endocrine disruptors
Measure of the frequency of endocrine disruptors assessed by european questionary QLK4-1999-01422 (simplified version )
Time frame: 1 day
comparison of cryptorchid and non-cryptorchid children born to parents with isolated exposure vs multiple exposures
Assessement by the Job-exposure matrix EDC (Environment disrupting chemicals)
Time frame: 1 day
Comparison of frequencies of exposure to endocrine disruptors (Environmental Disrupting Chemicals) in parents giving birth to a congenital cryptorchid child vs child not cryptorchid at birth but with secondary cryptorchidism.
presence of cryptorchidism at birth or secondarily
Time frame: 1 day
identify food exposure criteria (phytoestrogen or EDC pesticides) associated with the presence of a cryptorchid.
parents will be asked about their diet
Time frame: 1 day
Constitution of collection of biological samples from children with non-palpable bilateral cryptorchidism
The aim is only to make a collection of blood samples. Anonymous samples will be used later in order to improve knowledge of the cryptorchidism.
Time frame: 1 day
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier →